Baxter International Inc.
Baxter International Inc. BAX Peers
See (BAX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BAX | $30.15 | +0.58% | 15.5B | -57.97 | -$0.52 | +2.64% |
| ISRG | $558.21 | +0.05% | 200.1B | 81.97 | $6.81 | N/A |
| BDXA | $59.24 | -2.24% | 49.1B | 21.44 | $2.76 | +2.32% |
| BDX | $171.01 | +0.04% | 49B | 33.21 | $5.15 | +2.32% |
| ALC | $86.94 | +1.16% | 43B | 38.64 | $2.25 | +0.38% |
| RMD | $249.73 | -0.08% | 36.6B | 28.00 | $8.92 | +0.85% |
| WST | $218.56 | +3.37% | 15.7B | 34.36 | $6.36 | +0.38% |
| COO | $71.18 | +5.58% | 14.2B | 34.39 | $2.07 | N/A |
| HOLX | $63.07 | +0.80% | 14.1B | 26.50 | $2.38 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.32% |
Stock Comparison
BAX vs ISRG Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ISRG has a market cap of 200.1B. Regarding current trading prices, BAX is priced at $30.15, while ISRG trades at $558.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ISRG's P/E ratio is 81.97. In terms of profitability, BAX's ROE is -0.08%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, BAX is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs BDXA Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, BDXA has a market cap of 49.1B. Regarding current trading prices, BAX is priced at $30.15, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas BDXA's P/E ratio is 21.44. In terms of profitability, BAX's ROE is -0.08%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, BAX is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs BDX Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, BDX has a market cap of 49B. Regarding current trading prices, BAX is priced at $30.15, while BDX trades at $171.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas BDX's P/E ratio is 33.21. In terms of profitability, BAX's ROE is -0.08%, compared to BDX's ROE of +0.06%. Regarding short-term risk, BAX is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs ALC Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ALC has a market cap of 43B. Regarding current trading prices, BAX is priced at $30.15, while ALC trades at $86.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ALC's P/E ratio is 38.64. In terms of profitability, BAX's ROE is -0.08%, compared to ALC's ROE of +0.07%. Regarding short-term risk, BAX is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs RMD Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, RMD has a market cap of 36.6B. Regarding current trading prices, BAX is priced at $30.15, while RMD trades at $249.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas RMD's P/E ratio is 28.00. In terms of profitability, BAX's ROE is -0.08%, compared to RMD's ROE of +0.25%. Regarding short-term risk, BAX is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs WST Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, WST has a market cap of 15.7B. Regarding current trading prices, BAX is priced at $30.15, while WST trades at $218.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas WST's P/E ratio is 34.36. In terms of profitability, BAX's ROE is -0.08%, compared to WST's ROE of +0.17%. Regarding short-term risk, BAX is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs COO Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, COO has a market cap of 14.2B. Regarding current trading prices, BAX is priced at $30.15, while COO trades at $71.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas COO's P/E ratio is 34.39. In terms of profitability, BAX's ROE is -0.08%, compared to COO's ROE of +0.05%. Regarding short-term risk, BAX is less volatile compared to COO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs HOLX Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, HOLX has a market cap of 14.1B. Regarding current trading prices, BAX is priced at $30.15, while HOLX trades at $63.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas HOLX's P/E ratio is 26.50. In terms of profitability, BAX's ROE is -0.08%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs BDXB Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BAX is priced at $30.15, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BAX's ROE is -0.08%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, BAX is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs ATR Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ATR has a market cap of 10.1B. Regarding current trading prices, BAX is priced at $30.15, while ATR trades at $152.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ATR's P/E ratio is 27.90. In terms of profitability, BAX's ROE is -0.08%, compared to ATR's ROE of +0.15%. Regarding short-term risk, BAX is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs MASI Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, MASI has a market cap of 8.9B. Regarding current trading prices, BAX is priced at $30.15, while MASI trades at $164.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas MASI's P/E ratio is -30.18. In terms of profitability, BAX's ROE is -0.08%, compared to MASI's ROE of -0.41%. Regarding short-term risk, BAX is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs RGEN Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, RGEN has a market cap of 7.1B. Regarding current trading prices, BAX is priced at $30.15, while RGEN trades at $126.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas RGEN's P/E ratio is -309.02. In terms of profitability, BAX's ROE is -0.08%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, BAX is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs STVN Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, STVN has a market cap of 6.3B. Regarding current trading prices, BAX is priced at $30.15, while STVN trades at $23.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas STVN's P/E ratio is 44.58. In terms of profitability, BAX's ROE is -0.08%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BAX is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs MMSI Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, MMSI has a market cap of 5.6B. Regarding current trading prices, BAX is priced at $30.15, while MMSI trades at $95.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas MMSI's P/E ratio is 46.67. In terms of profitability, BAX's ROE is -0.08%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BAX is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs TFX Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, TFX has a market cap of 5.4B. Regarding current trading prices, BAX is priced at $30.15, while TFX trades at $122.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas TFX's P/E ratio is 37.91. In terms of profitability, BAX's ROE is -0.08%, compared to TFX's ROE of +0.03%. Regarding short-term risk, BAX is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs BLCO Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, BLCO has a market cap of 4.1B. Regarding current trading prices, BAX is priced at $30.15, while BLCO trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas BLCO's P/E ratio is -11.36. In terms of profitability, BAX's ROE is -0.08%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, BAX is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs HAE Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, HAE has a market cap of 3.4B. Regarding current trading prices, BAX is priced at $30.15, while HAE trades at $70.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas HAE's P/E ratio is 21.29. In terms of profitability, BAX's ROE is -0.08%, compared to HAE's ROE of +0.18%. Regarding short-term risk, BAX is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs ICUI Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ICUI has a market cap of 3.3B. Regarding current trading prices, BAX is priced at $30.15, while ICUI trades at $132.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ICUI's P/E ratio is -34.77. In terms of profitability, BAX's ROE is -0.08%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, BAX is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs XRAY Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, XRAY has a market cap of 3.2B. Regarding current trading prices, BAX is priced at $30.15, while XRAY trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas XRAY's P/E ratio is -3.56. In terms of profitability, BAX's ROE is -0.08%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, BAX is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs WRBY Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, WRBY has a market cap of 2.6B. Regarding current trading prices, BAX is priced at $30.15, while WRBY trades at $21.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas WRBY's P/E ratio is -176.75. In terms of profitability, BAX's ROE is -0.08%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, BAX is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs QDEL Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, QDEL has a market cap of 2B. Regarding current trading prices, BAX is priced at $30.15, while QDEL trades at $29.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas QDEL's P/E ratio is -5.72. In terms of profitability, BAX's ROE is -0.08%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, BAX is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs LMAT Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, BAX is priced at $30.15, while LMAT trades at $83.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas LMAT's P/E ratio is 42.36. In terms of profitability, BAX's ROE is -0.08%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, BAX is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs NVCR Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, BAX is priced at $30.15, while NVCR trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas NVCR's P/E ratio is -11.11. In terms of profitability, BAX's ROE is -0.08%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, BAX is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs ATRC Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ATRC has a market cap of 1.7B. Regarding current trading prices, BAX is priced at $30.15, while ATRC trades at $34.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ATRC's P/E ratio is -43.07. In terms of profitability, BAX's ROE is -0.08%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, BAX is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs AZTA Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, BAX is priced at $30.15, while AZTA trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas AZTA's P/E ratio is -8.65. In terms of profitability, BAX's ROE is -0.08%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, BAX is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs PLSE Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, PLSE has a market cap of 1.1B. Regarding current trading prices, BAX is priced at $30.15, while PLSE trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas PLSE's P/E ratio is -16.48. In terms of profitability, BAX's ROE is -0.08%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, BAX is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs KMTS Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, KMTS has a market cap of 1B. Regarding current trading prices, BAX is priced at $30.15, while KMTS trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas KMTS's P/E ratio is -10.40. In terms of profitability, BAX's ROE is -0.08%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, BAX is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs BLFS Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, BLFS has a market cap of 1B. Regarding current trading prices, BAX is priced at $30.15, while BLFS trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas BLFS's P/E ratio is -113.16. In terms of profitability, BAX's ROE is -0.08%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BAX is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs STAA Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, STAA has a market cap of 861.3M. Regarding current trading prices, BAX is priced at $30.15, while STAA trades at $17.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas STAA's P/E ratio is -12.08. In terms of profitability, BAX's ROE is -0.08%, compared to STAA's ROE of -0.18%. Regarding short-term risk, BAX is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs ATRI Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BAX is priced at $30.15, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BAX's ROE is -0.08%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, BAX is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs ANGO Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ANGO has a market cap of 445.5M. Regarding current trading prices, BAX is priced at $30.15, while ANGO trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ANGO's P/E ratio is -10.86. In terms of profitability, BAX's ROE is -0.08%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BAX is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs NNNN Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, NNNN has a market cap of 361.7M. Regarding current trading prices, BAX is priced at $30.15, while NNNN trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas NNNN's P/E ratio is 137.33. In terms of profitability, BAX's ROE is -0.08%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, BAX is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs NYXH Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, NYXH has a market cap of 290.5M. Regarding current trading prices, BAX is priced at $30.15, while NYXH trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas NYXH's P/E ratio is -3.40. In terms of profitability, BAX's ROE is -0.08%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, BAX is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs SMTI Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, SMTI has a market cap of 256.7M. Regarding current trading prices, BAX is priced at $30.15, while SMTI trades at $28.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas SMTI's P/E ratio is -21.55. In terms of profitability, BAX's ROE is -0.08%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, BAX is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs OSUR Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, OSUR has a market cap of 210.2M. Regarding current trading prices, BAX is priced at $30.15, while OSUR trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas OSUR's P/E ratio is -6.69. In terms of profitability, BAX's ROE is -0.08%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, BAX is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs STXS Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, STXS has a market cap of 193.3M. Regarding current trading prices, BAX is priced at $30.15, while STXS trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas STXS's P/E ratio is -7.25. In terms of profitability, BAX's ROE is -0.08%, compared to STXS's ROE of -2.17%. Regarding short-term risk, BAX is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs UTMD Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, UTMD has a market cap of 182M. Regarding current trading prices, BAX is priced at $30.15, while UTMD trades at $56.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas UTMD's P/E ratio is 14.79. In terms of profitability, BAX's ROE is -0.08%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, BAX is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs ZTEK Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ZTEK has a market cap of 152.3M. Regarding current trading prices, BAX is priced at $30.15, while ZTEK trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ZTEK's P/E ratio is -18.25. In terms of profitability, BAX's ROE is -0.08%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, BAX is more volatile compared to ZTEK. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs PDEX Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, PDEX has a market cap of 137.7M. Regarding current trading prices, BAX is priced at $30.15, while PDEX trades at $42.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas PDEX's P/E ratio is 15.30. In terms of profitability, BAX's ROE is -0.08%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BAX is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs KRMD Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, KRMD has a market cap of 135.7M. Regarding current trading prices, BAX is priced at $30.15, while KRMD trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas KRMD's P/E ratio is -24.50. In terms of profitability, BAX's ROE is -0.08%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, BAX is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs ZJYL Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ZJYL has a market cap of 124.8M. Regarding current trading prices, BAX is priced at $30.15, while ZJYL trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ZJYL's P/E ratio is 39.85. In terms of profitability, BAX's ROE is -0.08%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, BAX is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs INFU Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, INFU has a market cap of 124.7M. Regarding current trading prices, BAX is priced at $30.15, while INFU trades at $5.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas INFU's P/E ratio is 39.63. In terms of profitability, BAX's ROE is -0.08%, compared to INFU's ROE of +0.08%. Regarding short-term risk, BAX is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs MBOT Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, MBOT has a market cap of 97.4M. Regarding current trading prices, BAX is priced at $30.15, while MBOT trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas MBOT's P/E ratio is -4.18. In terms of profitability, BAX's ROE is -0.08%, compared to MBOT's ROE of -0.85%. Regarding short-term risk, BAX is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs MLSS Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, MLSS has a market cap of 70.8M. Regarding current trading prices, BAX is priced at $30.15, while MLSS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas MLSS's P/E ratio is -15.04. In terms of profitability, BAX's ROE is -0.08%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, BAX is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs AKYA Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, AKYA has a market cap of 56.6M. Regarding current trading prices, BAX is priced at $30.15, while AKYA trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas AKYA's P/E ratio is -1.18. In terms of profitability, BAX's ROE is -0.08%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, BAX is less volatile compared to AKYA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs OMIC Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BAX is priced at $30.15, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BAX's ROE is -0.08%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, BAX is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs IGAP Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BAX is priced at $30.15, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BAX's ROE is -0.08%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, BAX is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs DXR Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, DXR has a market cap of 42.3M. Regarding current trading prices, BAX is priced at $30.15, while DXR trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas DXR's P/E ratio is -97.22. In terms of profitability, BAX's ROE is -0.08%, compared to DXR's ROE of +0.02%. Regarding short-term risk, BAX is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs NEPH Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, NEPH has a market cap of 36.4M. Regarding current trading prices, BAX is priced at $30.15, while NEPH trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas NEPH's P/E ratio is 42.88. In terms of profitability, BAX's ROE is -0.08%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, BAX is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs POCI Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, POCI has a market cap of 34.3M. Regarding current trading prices, BAX is priced at $30.15, while POCI trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas POCI's P/E ratio is -4.92. In terms of profitability, BAX's ROE is -0.08%, compared to POCI's ROE of -0.54%. Regarding short-term risk, BAX is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs SDC Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BAX is priced at $30.15, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas SDC's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.08%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BAX is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs IVC Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BAX is priced at $30.15, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas IVC's P/E ratio is -0.79. In terms of profitability, BAX's ROE is -0.08%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BAX is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs FEMY Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, FEMY has a market cap of 21.8M. Regarding current trading prices, BAX is priced at $30.15, while FEMY trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas FEMY's P/E ratio is -0.88. In terms of profitability, BAX's ROE is -0.08%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, BAX is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs NXGLW Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, NXGLW has a market cap of 21.1M. Regarding current trading prices, BAX is priced at $30.15, while NXGLW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas NXGLW's P/E ratio is -0.19. In terms of profitability, BAX's ROE is -0.08%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, BAX is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs WOK Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, WOK has a market cap of 20.9M. Regarding current trading prices, BAX is priced at $30.15, while WOK trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas WOK's P/E ratio is -3.15. In terms of profitability, BAX's ROE is -0.08%, compared to WOK's ROE of -0.30%. Regarding short-term risk, BAX is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs RVP Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, RVP has a market cap of 19.8M. Regarding current trading prices, BAX is priced at $30.15, while RVP trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas RVP's P/E ratio is -0.87. In terms of profitability, BAX's ROE is -0.08%, compared to RVP's ROE of -0.27%. Regarding short-term risk, BAX is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs MHUA Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, MHUA has a market cap of 19.5M. Regarding current trading prices, BAX is priced at $30.15, while MHUA trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas MHUA's P/E ratio is 1.54. In terms of profitability, BAX's ROE is -0.08%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, BAX is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs HBIO Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, HBIO has a market cap of 18.2M. Regarding current trading prices, BAX is priced at $30.15, while HBIO trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas HBIO's P/E ratio is -0.31. In terms of profitability, BAX's ROE is -0.08%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, BAX is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs NXGL Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, NXGL has a market cap of 17.8M. Regarding current trading prices, BAX is priced at $30.15, while NXGL trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas NXGL's P/E ratio is -5.16. In terms of profitability, BAX's ROE is -0.08%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, BAX is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs LUCYW Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, LUCYW has a market cap of 13.8M. Regarding current trading prices, BAX is priced at $30.15, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.08%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, BAX is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs EKSO Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, EKSO has a market cap of 10.1M. Regarding current trading prices, BAX is priced at $30.15, while EKSO trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas EKSO's P/E ratio is -0.60. In terms of profitability, BAX's ROE is -0.08%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, BAX is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs POAI Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, POAI has a market cap of 8.5M. Regarding current trading prices, BAX is priced at $30.15, while POAI trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas POAI's P/E ratio is -0.66. In terms of profitability, BAX's ROE is -0.08%, compared to POAI's ROE of -5.91%. Regarding short-term risk, BAX is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs LUCY Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, LUCY has a market cap of 8.2M. Regarding current trading prices, BAX is priced at $30.15, while LUCY trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas LUCY's P/E ratio is 0.06. In terms of profitability, BAX's ROE is -0.08%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, BAX is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs STSS Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, STSS has a market cap of 5.9M. Regarding current trading prices, BAX is priced at $30.15, while STSS trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas STSS's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.08%, compared to STSS's ROE of -0.99%. Regarding short-term risk, BAX is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs NSTG Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BAX is priced at $30.15, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BAX's ROE is -0.08%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BAX is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs GCTK Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, GCTK has a market cap of 3.9M. Regarding current trading prices, BAX is priced at $30.15, while GCTK trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas GCTK's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.08%, compared to GCTK's ROE of +3.93%. Regarding short-term risk, BAX is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs GMVD Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $30.15, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BAX's ROE is -0.08%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs GMVDW Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BAX is priced at $30.15, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.08%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BAX is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs AVGR Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BAX is priced at $30.15, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BAX's ROE is -0.08%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, BAX is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for BAX.
BAX vs HRC Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BAX is priced at $30.15, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas HRC's P/E ratio is 41.92. In terms of profitability, BAX's ROE is -0.08%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BAX is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs ATRS Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BAX is priced at $30.15, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BAX's ROE is -0.08%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BAX is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs IIN Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BAX is priced at $30.15, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas IIN's P/E ratio is 226.45. In terms of profitability, BAX's ROE is -0.08%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BAX is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs APR Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, APR has a market cap of 0. Regarding current trading prices, BAX is priced at $30.15, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas APR's P/E ratio is 22.59. In terms of profitability, BAX's ROE is -0.08%, compared to APR's ROE of +9.81%. Regarding short-term risk, BAX is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.
BAX vs LMNX Comparison
BAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAX stands at 15.5B. In comparison, LMNX has a market cap of 0. Regarding current trading prices, BAX is priced at $30.15, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAX currently has a P/E ratio of -57.97, whereas LMNX's P/E ratio is N/A. In terms of profitability, BAX's ROE is -0.08%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, BAX is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for BAX.